Loading quotes...
Forecast
The analysts' average price target is €111.06 (+93.15%). The median is €110.76 (+92.63%).
| Buy |
11 |
| Hold |
0 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Vaxcyte expects Phase‑III data for pneumococcal candidate VAX‑31 by end of October
Vaxcyte announces it will release Phase‑III data for the 31‑valent pneumococcal vaccine VAX‑31 by the end of October and plans an investor package and a conference call to accompany the release. Management points to the expected coverage of about 95% of circulating serotypes as an advantage over Prevnar 20 (≈60%) and CAPVAXIVE (≈80%), but warns of regulatory and competitive risks. Manufacturing, the build‑out of the commercial team and a fully recruited infant Phase‑II program are proceeding on schedule; the company is taking incremental steps to prepare for a potential market launch. » More on de.investing.com
Vaxcyte bets on broader pneumococcal protection with VAX-31
At the Wells Fargo conference, Vaxcyte presented a strategy aimed at broader serotype coverage and stronger immune responses. Lead candidate VAX-31 is in Phase III; the company said OPUS-1 data could be available by the end of October 2024 and is expected to show coverage of around 95% of circulating pneumococcal strains (Prevnar 20 about 60%, CAPVAXIVE around 82%). Vaxcyte cites Phase II data showing roughly a 25% higher average immune response and emphasizes its cell-free protein synthesis platform; VAX-A1 against group A streptococcus is in Phase I. The company is targeting approval by the end of 2028, contingent on manufacturing consistency, and expects OPUS-2/OPUS-3 results in the first half of 2025. » More on de.investing.com
Vaxcyte CEO surrenders shares to cover taxes as company nears pivotal OPUS-1 readout
CEO Grant Pickering surrendered 6,289 Vaxcyte shares in a non‑discretionary transaction to cover tax withholdings on vested RSUs, leaving him with roughly 447,000 directly held shares and 266,430 indirectly held shares in trusts. Vaxcyte is preparing for topline OPUS-1 Phase 3 data on VAX-31 in the fourth quarter, a pivotal readout versus Pfizer and Merck that will determine filing timelines. The company reported high cash burn ($284.3m in the June quarter) but holds about $2.5bn in cash, making the trial outcome critical for its commercial prospects and cash runway. » More on finance.yahoo.com
Vaxcyte CFO surrenders shares to cover taxes while company reports $2.5bn cash and $605m half-year loss
President and CFO Andrew Guggenhime surrendered 2,705 Vaxcyte shares to satisfy tax withholding on vested RSUs; he retains about 164,321 shares total. Vaxcyte held $2.51 billion in cash and investments at end-June while reporting a six-month net loss of $604.9 million and rising operating expenses as it prepares manufacturing and clinical milestones. The company is advancing its lead candidate VAX-24 with key readouts expected later in the year that could validate recent buildout or leave the firm having pre-funded a product still awaiting pivotal data. » More on finance.yahoo.com
Vaxcyte faces make-or-break year as OPUS-1 readout arrives and losses widen
Vaxcyte's three Phase 3 trials of its pneumococcal candidate VAX-31 are fully enrolled, with OPUS-1 head-to-head readout versus Prevnar 20 and Capvaxive due in Q4 2026 and OPUS-2/3 results and a manufacturing consistency study extending into H1 2027. The company reported a net loss of $284.3 million for Q2, driven by higher R&D and G&A spending while preparing for a potential launch. Cash and investments stood at $2.5 billion as of June 30, and the board added vaccine veterans Moncef Slaoui and John Markels. Heavy short interest and some hedge fund trimming highlight market division ahead of the upcoming data catalysts. » More on finance.yahoo.com
Financials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -262.26m | 44.61% |
| EBITDA | -257.16m | 45.35% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €9.11bn |
Number of shares | 158.3m |
52-week high/low | €82.39 - €38.49 |
| Dividends | No |
Beta | 1.29 |
P/E ratio | -7.85 |
PEG ratio | 0.18 |
P/B ratio | 3.79 |
P/S ratio | 0.00 |
Company profile
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
| Name | Vaxcyte |
| CEO | Grant E. Pickering |
| Headquarters | San Carlos,
ca USA |
| Website | |
| Sector | Consumer Staples |
| Industry | Food Products |
| IPO | 12/06/2020 |
| Employees | 507 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | PCVX |
Frankfurt | 5VA.F |
Düsseldorf | 5VA.DU |
München | 5VA.MU |